These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26882069)

  • 1. High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma.
    Wang H; Wang L; Chi PD; Wang WD; Chen XQ; Geng QR; Xia ZJ; Lu Y
    Br J Cancer; 2016 Feb; 114(4):463-8. PubMed ID: 26882069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma.
    Wang L; Wang JH; Liu WJ; Wang WD; Wang H; Chen XQ; Geng QR; Lu Y; Xia ZJ
    Ann Hematol; 2017 Dec; 96(12):2079-2088. PubMed ID: 28871325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma.
    Wang L; Wang H; Chen H; Wang WD; Chen XQ; Geng QR; Xia ZJ; Lu Y
    Oncotarget; 2015 Dec; 6(38):41228-36. PubMed ID: 26515600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine profiles in patients with newly diagnosed multiple myeloma: Survival is associated with IL-6 and IL-17A levels.
    Gu J; Huang X; Zhang Y; Bao C; Zhou Z; Jin J
    Cytokine; 2021 Feb; 138():155358. PubMed ID: 33183958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group.
    Pelliniemi TT; Irjala K; Mattila K; Pulkki K; Rajamäki A; Tienhaara A; Laakso M; Lahtinen R
    Blood; 1995 Feb; 85(3):765-71. PubMed ID: 7530507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prognostic value of serum IL-6 in patients with multiple myeloma].
    Xing LJ; Xu Y; An G; Deng SH; Sui WW; Li F; Zhou DH; Zhao YZ; Qiu LG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1492-5. PubMed ID: 24370035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies.
    De Vita F; Orditura M; Galizia G; Romano C; Infusino S; Auriemma A; Lieto E; Catalano G
    Cancer; 1999 Nov; 86(10):1936-43. PubMed ID: 10570416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of interleukin-15 and interleukin-10 and their correlation with proliferating cell nuclear antigen in multiple myeloma.
    Pappa C; Miyakis S; Tsirakis G; Sfiridaki A; Alegakis A; Kafousi M; Stathopoulos EN; Alexandrakis MG
    Cytokine; 2007 Feb; 37(2):171-5. PubMed ID: 17446083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells.
    Mylin AK; Rasmussen T; Johansen JS; Knudsen LM; Nørgaard PH; Lenhoff S; Dahl IM; Johnsen HE;
    Eur J Haematol; 2006 Nov; 77(5):416-24. PubMed ID: 16930142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma.
    Nemunaitis J; Fong T; Shabe P; Martineau D; Ando D
    Cancer Invest; 2001; 19(3):239-47. PubMed ID: 11338880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High apelin levels could be used as a diagnostic marker in multiple myeloma: A comparative study.
    Maden M; Pamuk ON; Pamuk GE
    Cancer Biomark; 2016; 17(4):391-396. PubMed ID: 27689615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of Some Proliferation Markers and Some Prognostic Factors in Patients with Multiple Myeloma and their Impact on the Patients' Survival.
    Abdelgawad IA; Radwan NH; Shafik RE; Shokralla HA
    Asian Pac J Cancer Prev; 2016; 17(5):2389-94. PubMed ID: 27268602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum immunoreactive interleukin-6 and C-reactive protein levels in patients with multiple myeloma at diagnosis.
    Tienhaara A; Pulkki K; Mattila K; Irjala K; Pelliniemi TT
    Br J Haematol; 1994 Feb; 86(2):391-3. PubMed ID: 8199033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of interleukin-10 on admission as a prognostic predictor of human fulminant myocarditis.
    Nishii M; Inomata T; Takehana H; Takeuchi I; Nakano H; Koitabashi T; Nakahata J; Aoyama N; Izumi T
    J Am Coll Cardiol; 2004 Sep; 44(6):1292-7. PubMed ID: 15364334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum level of interleukin-35 as a potential prognostic factor for gastric cancer.
    Gu JH; Wang XG; Wang LQ; Zhou LN; Tang M; Li P; Wu XY; Chen MB; Zhang Y
    Asia Pac J Clin Oncol; 2021 Feb; 17(1):52-59. PubMed ID: 33044052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum IL-10 Predicts Worse Outcome in Cancer Patients: A Meta-Analysis.
    Zhao S; Wu D; Wu P; Wang Z; Huang J
    PLoS One; 2015; 10(10):e0139598. PubMed ID: 26440936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity.
    Alexandrakis MG; Passam FH; Kyriakou DS; Christophoridou AV; Perisinakis K; Hatzivasili A; Foudoulakis A; Castanas E
    Am J Hematol; 2004 Feb; 75(2):101-6. PubMed ID: 14755377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Changes in serum contents of interleukin-6 and interleukin-10 and their relation with occurrence of sepsis and prognosis of severely burned patients].
    Zhou H; Tu JJ; Huang Y; Chen XG; Deng YJ
    Zhonghua Shao Shang Za Zhi; 2012 Apr; 28(2):111-5. PubMed ID: 22781322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
    Urbańska-Ryś H; Wiersbowska A; Stepień H; Robak T
    Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated pretreatment serum levels of Il-10 are associated with a poor prognosis in Hodgkin's disease, the milan cancer institute experience.
    Viviani S; Notti P; Bonfante V; Verderio P; Valagussa P; Bonadonna G
    Med Oncol; 2000 Feb; 17(1):59-63. PubMed ID: 10713662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.